SCHEMBL8464790

SCHEMBL8464790

CC(=O)C(=CNC(N)=O)C(C)=O

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
TSHR P16473 3/20 0.38
BLM P54132 2/20 0.38
PMP22 Q01453 2/20 0.38
NFKB1 P19838 2/20 0.38
CA2 P00918 1/20 0.38
CYP3A4 P08684 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
CRBN Q96SW2 1/20 0.38
ALOX15 P16050 1/20 0.35
THPO P40225 2/20 0.32
CYP1A2 P05177 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096053 0.84 ALDH1A1 (0.34) LMNATSHRBLMPMP22NFKB1
SCHEMBL16536743 0.81
SCHEMBL24548415 0.79 CRBN (0.38) LMNATSHRBLMPMP22NFKB1
SCHEMBL22084139 0.78
SCHEMBL11406083 0.75 CA2 (0.35) LMNATSHRBLMPMP22NFKB1
SCHEMBL2297127 0.74 CRBN (0.38) LMNATSHRBLMPMP22NFKB1
SCHEMBL14294332 0.73 CRBN (0.33) LMNABLMPMP22CRBNALOX15
SCHEMBL13801727 0.72
SCHEMBL8956992 0.72 CRBN (0.48) LMNATSHRBLMPMP22NFKB1
SCHEMBL26884 0.72 CRBN (0.36) LMNATSHRBLMPMP22NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5877210-A CONTROLLING IMMUNE RESPONSE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-02 US claimed
US-5583242-A VANADYL COMPLEXES BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 US claimed
US-5565491-A FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-15 US claimed
US-20230241078-A1 Vanadyl and vanadate for use in reducing stress-induced metabolic derangement CFM PHARMA HOLDING B.V. (NL) 2023-08-03 US disclosed
US-20200246352-A1 Vanadyl and vanadate for use in reducing stress-induced metabolic derangement CFM PHARMA HOLDING B.V. (NL) 2020-08-06 US disclosed
EP-3684352-A1 VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT CFM Pharma Holding BV (NL) 2020-07-29 EP disclosed
WO-2019059770-A1 VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT CFM PHARMA HOLDING B.V. (NL) 2019-03-28 WO disclosed
US-5877210-A CONTROLLING IMMUNE RESPONSE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-02 US disclosed
US-5846998-A Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation BRISTOL-MYERS SQUIBB COMPANY (US) 1998-12-08 US disclosed
US-5693627-A TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS BRISTOL-MYERS SQUIBB COMPANY (US) 1997-12-02 US disclosed
US-5583242-A VANADYL COMPLEXES BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 US disclosed
US-5565491-A FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-15 US disclosed
WO-1995020390-A1 USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION BRISTOL-MYERS SQUIBB COMPANY (US) 1995-08-03 WO disclosed